[Cutaneous manifestations of metabolic syndrome].

Hautarzt

SMZ Ost, Abteilung für Dermatologie, Donauspital, Langobardenstr. 122, 1220, Wien, Österreich.

Published: December 2016

Background: Metabolic syndrome (MetS) is a cluster of risk factors which increase the risk of developing cardiovascular diseases and type II diabetes mellitus. High blood pressure, hyperglycemia, dyslipidemia, and central obesity are the main risk factors. While MetS is not a dermatological diagnosis per se, several cutaneous manifestations can serve as a clinical indicator for impending MetS and facilitate an early diagnosis and therapy in order to prevent its long-term sequelae.

Cutaneous Manifestations: Acanthosis nigricans and multiple skin tags can be signs of insulin resistance and impaired glucose tolerance, xanthoma and xanthelasma signs of dyslipidemia. Patients with type II diabetes can display numerous more or less specific dermatoses. Psoriasis and Hidradenitis suppurativa are frequently associated with MetS and obesity. Acne and hirsutism are highly prevalent signs of cutaneous hyperandrogenism due to polycystic ovary syndrome (PCOS). Hyperinsulinemia plays a major pathophysiological role in PCOS; MetS is thus an integral part of PCOS CONCLUSION: Emerging scientific evidence points to close associations between MetS and common dermatological diseases necessitating to integrate this perspective into clinical management of these diseases. The dermatologist is a key player in early detection of MetS.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-016-3891-2DOI Listing

Publication Analysis

Top Keywords

risk factors
8
type ii diabetes
8
mets
7
[cutaneous manifestations
4
manifestations metabolic
4
metabolic syndrome]
4
syndrome] background
4
background metabolic
4
metabolic syndrome
4
syndrome mets
4

Similar Publications

Purpose Of Review: Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association.

View Article and Find Full Text PDF

Growing Pains: The Incidence and Prevalence of Myopia from 1950 to 2050.

J Binocul Vis Ocul Motil

January 2025

Ross Eye Institute, University at Buffalo, Buffalo, New York.

Myopia has been included as one of the five serious ocular conditions leading to blindness. Prevalence of myopia (between -0.50D and -5.

View Article and Find Full Text PDF

The role of the early-life gut microbiome in childhood asthma.

Gut Microbes

December 2025

Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital, Herlev-Gentofte, Gentofte, Denmark.

Asthma is a chronic disease affecting millions of children worldwide, and in severe cases requires hospitalization. The etiology of asthma is multifactorial, caused by both genetic and environmental factors. In recent years, the role of the early-life gut microbiome in relation to asthma has become apparent, supported by an increasing number of population studies, research, and intervention trials.

View Article and Find Full Text PDF

Objective: To quantify treatment preferences for food allergy management options (oral immunotherapy, biologic therapy, and allergen avoidance), overall and by sociodemographic strata.

Methods: A US general population (≥13 years) discrete choice experiment (DCE) conducted comprised of 12 treatment-feature focused DCE choice sets; the Intolerance of Uncertainty─12 Scale (IUS-12); and clinical/demographic questions. Conditional logistic regression analyses were conducted overall and by age, income, urbanization, educational attainment, food and other sociodemographic factors, and presented as odds ratios (ORs) with 95% confidence intervals (CIs).

View Article and Find Full Text PDF

Improving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.

Curr Med Res Opin

January 2025

Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.

Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!